Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis.
Study Goal
The researchers aimed to determine if N-acetylcysteine could neutralize the oxidative and inflammatory effects of iron administration during haemodialysis.
Results Summary
N-acetylcysteine significantly reduced malondialdehyde levels (a marker of oxidative stress) when administered with a low iron dose (50 mg), but had no effect on other inflammatory or endothelial dysfunction markers. Haemodialysis itself increased oxidative stress and inflammation, while iron had minor effects on inflammation and oxidative stress.
Population
40 patients undergoing haemodialysis.
Effective Dosage
Not specified (infused before iron sucrose at 50 or 100 mg).
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Haemodialysis | increase | plasma vWF | patients undergoing haemodialysis | P < 0.001 | produced significant increase | #1 |
Haemodialysis | increase | sICAM-1 | patients undergoing haemodialysis | P < 0.001 | produced significant increase | #2 |
Haemodialysis | increase | malondialdehyde | patients undergoing haemodialysis | P < 0.001 | produced significant increase | #3 |
Haemodialysis | increase | IL-8 | patients undergoing haemodialysis | P < 0.001 | produced significant increase | #4 |
Haemodialysis | increase | CD11b/CD18 expression in monocytes | patients undergoing haemodialysis | P < 0.001 | produced significant increase | #5 |
Haemodialysis | decrease | total antioxidant capacity | patients undergoing haemodialysis | P < 0.001 | decrease | #6 |
Iron | increase | plasma malondialdehyde | patients undergoing haemodialysis | - | induced significant increase | #7 |
Iron | increase | IL-8 in monocytes | patients undergoing haemodialysis | - | induced significant increase | #8 |
Iron | no change | total antioxidant capacity | patients undergoing haemodialysis | - | had no effect | #9 |
Iron | no change | CD11b/CD18 expression | patients undergoing haemodialysis | - | had no effect | #10 |
Iron | no change | plasma IL-8 | patients undergoing haemodialysis | - | had no effect | #11 |
Iron | no change | vWF | patients undergoing haemodialysis | - | had no effect | #12 |
Iron | no change | sICAM-1 | patients undergoing haemodialysis | - | had no effect | #13 |
N-acetylcysteine | decrease | malondialdehyde | patients undergoing haemodialysis | P = 0.040 | produced a significant decrease | #14 |
Standard (100 mg) and low (50 mg) doses of iron during haemodialysis | no change | endothelium | patients undergoing haemodialysis | - | had no effects | #15 |
Iron | increase | inflammation | patients undergoing haemodialysis | - | only had minor effects | #16 |
Iron | increase | oxidative stress | patients undergoing haemodialysis | - | produced an increase | #17 |
N-acetylcysteine | decrease | oxidative stress | patients undergoing haemodialysis | - | neutralized | #18 |
Haemodialysis | increase | oxidative stress | patients undergoing haemodialysis | - | caused a significant increase | #19 |
Haemodialysis | increase | inflammation | patients undergoing haemodialysis | - | caused a significant increase | #20 |
Haemodialysis | increase | endothelial dysfunction markers | patients undergoing haemodialysis | - | caused a significant increase | #21 |
AIM: Haemodialysis induces endothelial dysfunction by oxidation and inflammation. Intravenous iron administration during haemodialysis could worsen endothelial dysfunction. The aim of this study was to ascertain if iron produces endothelial dysfunction and the possible neutralizing effect of N-acetylcysteine when infused before iron. The oxidative and inflammatory effects of iron during haemodialysis were also assessed. METHODS: Forty patients undergoing haemodialysis were studied in a randomized and cross-over design with and without N-acetylcysteine infused before iron sucrose (50 or 100 mg). Plasma Von Willebrand factor (vWF), soluble intercellular adhesion molecule-1 (sICAM-1) levels, malondialdehyde, total antioxidant capacity, CD11b/CD18 expression in monocytes, interleukin (IL)-8 in monocytes and plasma IL-8 were studied at baseline and during haemodialysis. RESULTS: Haemodialysis produced significant (P < 0.001) increase in plasma vWF, sICAM-1, malondialdehyde, IL-8 and CD11b/CD18 expression in monocytes, as well as decrease in total antioxidant capacity. Iron induced significant increase in plasma malondialdehyde and IL-8 in monocytes, but had no effect on total antioxidant capacity, CD11b/CD18 expression, plasma IL-8, vWF and sICAM-1. The addition of N-acetylcysteine to 50 mg of iron produced a significant (P = 0.040) decrease in malondialdehyde. CONCLUSION: Standard (100 mg) and low (50 mg) doses of iron during haemodialysis had no effects on endothelium. Iron only had minor effects on inflammation and produced an increase in oxidative stress, which was neutralized by N-acetylcysteine at low iron dose. Haemodialysis caused a significant increase in oxidative stress, inflammation and endothelial dysfunction markers.